Treatment advances for hematologic malignancies (HM) have dramatically improved life expectancy, necessitating greater focus on long-term cancer pain management. This study explored real-world patterns of opioid use among patients with HM.
Methods
This retrospective cohort study identified adults diagnosed with HM from January 1, 2013 through December 31, 2019 using the Truven MarketScan Commercial Claims and Encounters database. Across several HM types, we described rates of high-risk opioid use (based on Pharmacy Quality Alliance measures) and opioid-related harms, including incident opioid use disorder (OUD) diagnoses and opioid-related hospitalizations or emergency department (ED) visits. We used multivariable Cox regression to generate adjusted hazard ratios and 95% confidence intervals comparing the risk of opioid-related harms between patients with versus without high-risk opioid use.
Results
Our sample included 43,190 patients with HM. Median age at HM diagnosis was 54 years (interquartile range = 44–60). Most patients (61.9%) were diagnosed with lymphoma. Approximately half (49.2%) had an opioid dispensed in the follow-up period. Among all patients, 20.0% met criteria for high-risk opioid use, 0.9% had an OUD diagnosis, and 0.3% experienced an opioid-related hospitalization/ED visit in follow-up. High-risk opioid use increased the risk of an OUD diagnosis by 3.3 times (p < 0.0001) and an opioid-related hospitalization/ED visit 4.2 times (p < 0.0001).
Conclusion
High-risk opioid use was prevalent among patients with HM and significantly increased the risk of opioid-related harms. However, rates of opioid-related harms were low. These findings highlight the importance of continually monitoring pain and opioid use throughout HM survivorship to provide safe, effective HM pain management.
MeghaniSHVapiwalaN. Bridging the critical divide in pain management guidelines from the CDC, NCCN, and ASCO for cancer survivors. JAMA Oncol2018; 4: 1323–1324.
7.
CareyCMJenaABBarnettML. Patterns of potential opioid misuse and subsequent adverse outcomes in medicare, 2008 to 2012. Ann Intern Med2018; 168: 837–845.
8.
ChouR, et al.The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a national institutes of health pathways to prevention workshop. Ann Intern Med2015; 162: 276–286.
9.
ElsC, et al.Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of cochrane reviews. Cochrane Database Syst Rev2017; 10: CD012509.
10.
BallantyneJC. Chronic pain following treatment for cancer: the role of opioids. Oncologist2003; 8: 567–575.
11.
WiffenPJ, et al.Opioids for cancer pain - an overview of Cochrane reviews. Cochrane Database Syst Rev2017; 7: CD012592.
12.
LorenAW. Harder to treat than leukemia - opioid use disorder in survivors of cancer. N Engl J Med2018; 379: 2485–2487.
13.
SutradharRLokkuABarberaL. Cancer survivorship and opioid prescribing rates: a population-based matched cohort study among individuals with and without a history of cancer. Cancer2017; 123: 4286–4293.
14.
MoyoP, et al.Opioid prescribing safety measures in medicaid enrollees with and without cancer. Am J Prev Med2019; 57: 540–544.
15.
TsaiSY, et al.Persistent and new-onset daytime sleepiness in pregnant women: a prospective observational cohort study. Int J Nurs Stud2017; 66: 1–6.
16.
ShahR, et al.Long-term opioid therapy in older cancer survivors: a retrospective cohort study. J Am Geriatr Soc2019; 67: 945–952.
17.
RobertsAW, et al.Opioid use disorder and overdose in older adults with breast, colorectal, or prostate cancer. J Natl Cancer Inst2021 Apr 6; 113(4): 425–433. doi:https://doi.org/10.1093/jnci/djaa122
PulteDJansenLBrennerH. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J2020; 10: 56.
20.
FarrukhN, et al.Pain in older survivors of hematologic malignancies after blood or marrow transplantation: a BMTSS report. Cancer2020; 126: 2003–2012.
21.
SweissKKurzweilKCalipGS,et al.Chronic opioid use is highly prevalent in patients undergoing allogeneic transplant and impacts long term outcomes. Blood2021; 138: 1823.
22.
Shoemaker-HuntS, et al.Developing clinical quality improvement measures aligned with the CDC guideline for prescribing opioids for chronic pain: an important strategy to support safer prescribing in primary care. Am J Med Qual2021; 36: 125–128.
Centers for Disease Control and Prevention (CDC) and National Center for Health Statistics (NCHS). 2017. NCHS Urban-Rural Classification Scheme for Counties. Accessed April 23, 2023 fromhttps://www.cdc.gov/nchs/data_access/urban_rural.htm.
27.
HootenWM, et al.A conceptual framework for understanding unintended prolonged opioid use. Mayo Clin Proc2017; 92: 1822–1830.
28.
DowellDHaegerichTMChouR. CDC Guideline for prescribing opioids for chronic pain - United States, 2016. MMWR Recomm Rep2016; 65: 1–49.
29.
WebsterLR. Risk factors for opioid-use disorder and overdose. Anesth Analg2017; 125: 1741–1748.
30.
WebsterLRWebsterRM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med2005; 6: 432–442.
31.
VitzthumLK, et al.Predicting persistent opioid use, abuse and toxicity among cancer survivors. J Natl Cancer Inst2020 Jul 1; 112(7): 720–727. doi:https://doi.org/10.1093/jnci/djz200
32.
WilseyBL, et al.Psychological comorbidities predicting prescription opioid abuse among patients in chronic pain presenting to the emergency department. Pain Med2008; 9: 1107–1117.
33.
MusichS, et al.Characteristics associated with transition from opioid initiation to chronic opioid use among opioid-naive older adults. Geriatr Nurs2019; 40: 190–196.
34.
HairJFBlackWCBabinBJ,et al.Multivariate data analysis, vol. 3. Upper Saddle River, NJ: Prentice Hall, 1998.
35.
MuenchJ, et al.Assessment of opioid prescribing patterns in a large network of US community health centers, 2009 to 2018. JAMA Netw Open2020; 3: e2013431.
36.
VadieiNBhattacharjeeS. Concurrent opioid and benzodiazepine utilization patterns and predictors among community-dwelling adults in the United States. Psychiatr Serv2020; 71: 1011–1019.
37.
ColuzziFRolkeRMercadanteS. Pain management in patients with multiple myeloma: an update. Cancers (Basel)2019 Dec 17; 11(12): 2037. doi:https://doi.org/10.3390/cancers11122037
38.
NewellLFCookRJ. Advances in acute myeloid leukemia. BMJ2021; 375: n2026.
39.
NiscolaP, et al.Epidemiology, features and outcome of pain in patients with advanced hematological malignancies followed in a home care program: an Italian survey. Ann Hematol2007; 86: 671–676.
40.
NiscolaP, et al.Epidemiology of pain in hospital haematological setting: an Italian survey. Leuk Res2008; 32: 197–198.
41.
ShaulovA, et al.Pain in patients with newly diagnosed or relapsed acute leukemia. Support Care Cancer2019; 27: 2789–2797.
42.
HayesCJ, et al.Impact of opioid dose escalation on pain intensity: a retrospective cohort study. Pain2020; 161: 979–988.
43.
Agency for Healthcare Research and Quality (AHRQ). 2022. Rockville, MD. Healthcare cost and utilization project (HCUP). Accessed April 23, 2023 fromhttps://www.ahrq.gov/data/hcup/index.html.
44.
EdlundMJ, et al.The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain2014; 30: 557–564.
45.
DunnKM, et al.Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med2010; 152: 85–92.
46.
JonesCM, et al.Naloxone co-prescribing to patients receiving prescription opioids in the medicare part D program, United States, 2016-2017. JAMA2019; 322: 462–464.
47.
JonesTLookatchSMooreT. Validation of a new risk assessment tool: the brief risk questionnaire. J Opioid Manag2015; 11: 171–183.
48.
RobertoA, et al.Living systematic review to assess the analgesic undertreatment in cancer patients. Pain Pract2022 Apr; 22(4): 487–496. doi:https://doi.org/10.1111/papr.13098
49.
JohnsenAT, et al.Health related quality of life in a nationally representative sample of haematological patients. Eur J Haematol2009; 83: 139–148.
50.
ManittaV, et al.The symptom burden of patients with hematological malignancy: a cross-sectional observational study. J Pain Symptom Manage2011; 42: 432–442.
51.
CostantiniM, et al.Prevalence, distress, management, and relief of pain during the last 3 months of cancer patients’ life. Results of an Italian mortality follow-back survey. Ann Oncol2009; 20: 729–735.
52.
GeyerHLGazelkaHMesaR. How I treat pain in hematologic malignancies safely with opioid therapy. Blood2020; 135: 2354–2364.
53.
OechsleK. Palliative care in patients with hematological malignancies. Oncol Res Treat2019; 42: 25–30.
54.
SteinKD, et al.Sociodemographic inequalities in barriers to cancer pain management: a report from the American Cancer Society’s Study of Cancer Survivors-II (SCS-II). Psychooncology2016; 25: 1212–1221.
55.
BlancoCVolkowND. Management of opioid use disorder in the USA: present status and future directions. Lancet2019; 393: 1760–1772.
56.
RichardsGC, et al.Factors associated with the prescribing of high-dose opioids in primary care: a systematic review and meta-analysis. BMC Med2020; 18: 68.
57.
KarmaliRN, et al.Long-term opioid therapy definitions and predictors: a systematic review. Pharmacoepidemiol Drug Saf2020; 29: 252–269.
El-JawahriA, et al.Palliative and end-of-life care for patients with hematologic malignancies. J Clin Oncol2020; 38: 944–953.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
